Why the study?
Does sacubitril-valsartan reduce NT-proBNP concentration in patients with HFrEF hospitalized for acute decompensated heart failure compared to enalapril?
Population
881 patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated…
Comparison
Sacubitril-valsartan vs Enalapril (target dose, 10 mg twice daily)
Design
RCT, randomly assigned
Follow-up
8 weeks
Key result
Sacubitril-valsartan led to a greater reduction in NT-proBNP concentration than enalapril (ratio of change 0.71; 95% CI 0.63-0.81; P<0.001) in patients with acute decompensated heart failure.
Authors
Loading...
Supports in-hospital initiation of sacubitril-valsartan in acute decompensated HF; extends prior chronic HF evidence to hospitalized patients.
RCT (n=881)
Yes
Does sacubitril-valsartan reduce NT-proBNP concentration in patients with HFrEF hospitalized for acute decompensated heart failure compared to enalapril?
Effect estimate: ratio of change 0.71 (95% CI 0.63 to 0.81)
Absolute Event Rate: -46.7% vs -25.3%
p-value: p=<0.001
In patients hospitalized for acute decompensated HFrEF, initiation of sacubitril-valsartan led to a significantly greater reduction in NT-proBNP compared to enalapril, with a similar safety profile.
Velazquez et al. (2018) conducted an RCT in Acute decompensated heart failure (n=881). Sacubitril-valsartan vs. Enalapril (target dose, 10 mg twice daily) was evaluated on Time-averaged proportional change in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration from baseline through weeks 4 and 8 (ratio of change 0.71, 95% CI 0.63 to 0.81, p=<0.001). Sacubitril-valsartan led to a greater reduction in NT-proBNP concentration than enalapril (ratio of change 0.71; 95% CI 0.63-0.81; P<0.001) in patients with acute decompensated heart failure.